Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
Thiazide-induced potassium loss may contribute to new onset diabetes (NOD). KCNJ1 encodes a potassium channel and one study observed that a KCNJ1 single-nucleotide polymorphism (SNP) was associated with changes in fasting glucose (FG) during hydrochlorothiazide (HCTZ) treatment. We used linear regression to test association of KCNJ1 SNPs and haplotypes with FG changes during HCTZ treatment in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. We used logistic regression to test association of KCNJ1 variation with NOD in HCTZ-treated patients from the International Verapamil SR Trandolapril Study (INVEST). Multivariate regression analyses were performed by race/ethnicity with false discovery rate (FDR) correction. In PEAR blacks, a KCNJ1 SNP was associated with increased FG during HCTZ treatment (beta=8.47, P(FDR)=0.009). KCNJ1 SNPs and haplotypes were associated with NOD risk in all INVEST race/ethnic groups (strongest association: odds ratio 2.14 (1.31-3.53), P(FDR)=0.03). Our findings support that KCNJ1 variation is associated with HCTZ-induced dysglycemia and NOD.
Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida College of Pharmacy, Gainesville, FL, USA.
J H
JH
Karnes
C W
CW
McDonough
Y
Y
Gong
T T
TT
Vo
T Y
TY
Langaee
A B
AB
Chapman
J G
JG
Gums
A L
AL
Beitelshees
K R
KR
Bailey
J L
JL
Del-Aguila
E A
EA
Boerwinkle
C J
CJ
Pepine
S T
ST
Turner
J A
JA
Johnson
R M
RM
Cooper-DeHoff
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D005215:Fasting / Q000378:metabolism*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006239:Haplotypes; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics / Q000379:methods; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics* / Q000378:metabolism; D011446:Prospective Studies; D014700:Verapamil / Q000627:therapeutic use
D000959:Antihypertensive Agents; C086989:KCNJ1 protein, human; D024661:Potassium Channels, Inwardly Rectifying; D006852:Hydrochlorothiazide; D001262:Atenolol; D014700:Verapamil; D005947:Glucose